Results 31 to 40 of about 366,020 (324)

Prostate-Specific Antigen in Prostate Cancer

The International Journal of Biological Markers, 1986
Prostate-specific antigen (PA) has been evaluated clinically as a tumor marker of prostate cancer with the use of enzyme immunoassay (EIA). For serodetection of prostate cancer, PA was assayed in a total of 1,109 sera. From mean ± 3 S.D.
Manabu Kuriyama
doaj   +1 more source

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan

Asian Journal of Andrology, 2014
To clarify the recent trends in prostate-specific antigen (PSA) distribution in men in Japan, we analyzed the PSA distributions of men undergoing PSA-based population screening.
Yasuhide Kitagawa, Kazuaki Machioka, Hiroshi Yaegashi, Kazufumi Nakashima, Mitsuo Ofude, Kouji Izumi, Satoru Ueno, Yoshifumi Kadono, Hiroyuki Konaka, Atsushi Mizokami, Mikio Namiki   +10 more
doaj   +1 more source

Prostate-specific antigen and free prostate-specific antigen/prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer

Baghdad Journal of Biochemistry and Applied Biological Sciences, 2020
Background: Prostate cancer is one of the most common cancers in men, worldwide. Many markers are suggested for prostate cancer with different specificity and sensitivity.
Amal A. Hussein, Rayah Baban, Alaa Hussein   +2 more
doaj  

What Should Be the Prostate Specific Antigen Threshold for Prostate Biopsy?

Haseki Tıp Bülteni, 2017
Aim: There is still uncertainty today regarding the prostate specific antigen (PSA) threshold for prostate biopsy. From this point of view, we aimed to investigate the PSA threshold for prostate biopsy in this study.
Hasan Deliktaş, Hayrettin Şahin
doaj   +1 more source

Clinical Implications of Nadir Serum Prostate-Specific Antigen Levels After Transurethral Enucleation of the Prostate

Frontiers in Oncology, 2022
ObjectiveProstate-specific antigen levels after transurethral enucleation of the prostate may serve as indicators of residual cancer foci. The objective of this study was to investigate the association between the post-transurethral enucleation of the ...
Yung-Ting Cheng, Yung-Ting Cheng, Jian-Hua Hong, Yu-Chuan Lu, Yi-Kai Chang, Shih-Chun Hung, Kuo-Kang Feng, Shih-Ping Liu, Po-Ming Chow, Hong-Chiang Chang, Chung-Hsin Chen, Yeong-Shiau Pu   +11 more
doaj   +1 more source

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

BMC Cancer, 2019
Background Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer potentially have financial and ...
Joshua P. Schiff, Patrick Cotogno, Allison Feibus, Peter Steinwald, Elisa Ledet, Brian Lewis, Oliver Sartor   +6 more
doaj   +1 more source

Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients [PDF]

, 2013
<br>Background:Prostate cancer cell growth is dependent upon androgen receptor (AR) activation, which is regulated by specific kinases. The aim of the current study is to establish if AR phosphorylation by Cdk1 or ERK1/2 is of prognostic ...
BV Kallakury, C E Adams, C Tannahill, D Gioeli, D Gioeli, G Fyffe, GG Kuiper, H Y Leung, H Zong, HY Wong, J Edwards, J Ferlay, J M Willder, JC Obenauer, JS Diallo, K Shigemura, KS McCarty, LA Ponguta, LJ Blok, M A Underwood, M Mistry, M Roach, M Seywright, MS Cookson, NG Anderson, P Chymkowitch, P G Horgan, P McCall, R Mukherjee, RE Bakin, RK Tyagi, S Chen, S Chen, S J Heng, SM Powell, T Kirkegaard, T Ohta, WC Bell, Y Wen, Z Fu, ZX Zhou   +40 more
core   +1 more source

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

IJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani, Yujiro Hayashi, Airi Miki, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Tetsuya Takao   +7 more
doaj   +1 more source

Death receptor 5 expression is inversely correlated with prostate cancer progression. [PDF]

, 2014
Prostate carcinoma (PCa) is one of the most common cancers in men. Prostate-specific antigen (PSA) has been widely used to predict the outcome of PCa and screening with PSA has resulted in a decline in mortality. However, PSA is not an optimal prognostic
Antonio-Andres, Gabriela, Bonavida, Benjamin, Gonzalez-Bonilla, Cesar, Hernandez-Cueto, Angeles, Hernandez-Cueto, Daniel, Huerta-Yepez, Sara, Jimenez-Gutierrez, Carlos, Mendoza-Marin, Marisela, Mora-Campos, Rosario, Sandoval-Mejia, Ana Lilia, Vega, Mario I   +10 more
core   +1 more source